Limited Edition Golden Llama is here! Check out how you can get one.
Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free!
Offering SPR-BLI Services - Proteins provided for free!
Here come GMP Grade Cytokines!Free Sample is available!
Here come GMP Grade Cytokines!Free Sample is available!
Human IL-23A&IL-12B Heterodimer Protein, premium grade (Cat. No. ILB-H5219) stimulates proliferation of Human IL-23 R/IL-12 R beta 1(Luc) HEK293 Reporter Cell. The specific activity of Human IL-23A&IL-12B Heterodimer Protein, premium grade is > 1.80 X 10^3 U/mg (QC tested).
Captured Biotinylated Human IL-23A&IL-12B Heterodimer Protein, His,Avitag&Tag Free (Cat. No. ILB-H82W6) on Biotin CAP - Series S sensor Chip can bind Human IL-23 R, His Tag (Cat. No. ILR-H52H4) affinity constant of 4.77 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Captured Human IL-23 R, Fc Tag (Cat. No. ILR-H5254) on CM5 chip via anti-human IgG Fc antibodies surface can bind Human IL-23A&IL-12B Heterodimer Protein, His Tag&Tag Free (Cat. No. ILB-H52W5) with an affinity constant of 5.36 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Ustekinumab | C-340; CNTO-1275 | Approved | Johnson & Johnson Innovative Medicine | Stelara, 喜达诺 | United States | Plaque psoriasis | Janssen Biotech Inc | 2009-09-25 | Multiple Sclerosis; Plaque psoriasis; Dermatitis, Atopic; Crohn Disease; Hidradenitis Suppurativa; Common Variable Immunodeficiency; Uveitis; Colitis, Ulcerative; Arthritis, Psoriatic; Takayasu Arteritis; Lupus Erythematosus, Systemic; Psoriasis; Diabetes Mellitus, Type 1; Arthritis, Juvenile; Sjogren's Syndrome; Spondylitis, Ankylosing; Pouchitis; Ichthyosis; Dermatomyositis; Inflammatory Bowel Diseases; Type I Leukocyte Adhesion Defect; Polymyositis; Liver Cirrhosis, Biliary | Details |
Ustekinumab biosimilar(Formycon) | FYB-202 | Approved | Formycon AG | OTULFI | EU | Crohn Disease; Colitis, Ulcerative | Fresenius Kabi Deutschland Gmbh, Formycon AG | 2024-09-25 | Arthritis, Psoriatic; Colitis, Ulcerative; Plaque psoriasis; Crohn Disease | Details |
Ustekinumab Biosimilar (qyuns) | QX-001S; QX-001-S; HDM-3001 | Approved | Qyuns Therapeutics Co Ltd | Mainland China | Plaque psoriasis | Qyuns Therapeutics Co Ltd | 2024-10-29 | Psoriasis; Plaque psoriasis | Details | |
Ustekinumab Biosimilar(Celltrion) | CT-P43 | Approved | Celltrion Inc | Steqeyma, Steqeyma IV | Canada | Plaque psoriasis; Arthritis, Psoriatic; Crohn Disease | Celltrion Inc | 2024-08-01 | Psoriasis; Arthritis, Psoriatic; Colitis, Ulcerative; Plaque psoriasis; Crohn Disease | Details |
Ustekinumab biosimilar (Biocon) | Approved | Biocon Biologics Ltd | Bmab 1200, Yesintek | United States | Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease | Biocon Biologics Inc | 2024-11-29 | Psoriasis; Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease; Plaque psoriasis | Details | |
Ustekinumab biosimilar (Alvotech) | AVT04; AVT-04 | Approved | Alvotech hf | Jamteki, Uzpruvo, SELARSDI™, JamtekiTM, Ustekinumab BS (F) | Japan | Arthritis, Psoriatic; Psoriasis | Fuji Pharma Co Ltd | 2023-09-25 | Psoriasis; Arthritis, Psoriatic; Colitis, Ulcerative; Plaque psoriasis; Crohn Disease | Details |
Ustekinumab biosimilar(Amgen) | ABP-654 | Approved | Amgen Inc | Wezlana, WEZLANA, wezenla | United States | Crohn Disease; Colitis, Ulcerative; Arthritis, Psoriatic; Plaque psoriasis | Amgen Inc | 2023-10-31 | Psoriasis; Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease; Plaque psoriasis | Details |
Ustekinumab biosimilar(DM Bio) | DA-3115; DMB-3115 | Approved | Dong-A Pharmaceutical Co Ltd, Meiji Seika Pharma Co Ltd | IMULDOSA, Absimky | United States | Psoriasis | Dong-A ST Co Ltd, Meiji Seika Kaisha Ltd | 2024-10-11 | Psoriasis; Colitis, Ulcerative; Crohn Disease | Details |
Ustekinumab | C-340; CNTO-1275 | Approved | Johnson & Johnson Innovative Medicine | Stelara, 喜达诺 | United States | Plaque psoriasis | Janssen Biotech Inc | 2009-09-25 | Multiple Sclerosis; Plaque psoriasis; Dermatitis, Atopic; Crohn Disease; Hidradenitis Suppurativa; Common Variable Immunodeficiency; Uveitis; Colitis, Ulcerative; Arthritis, Psoriatic; Takayasu Arteritis; Lupus Erythematosus, Systemic; Psoriasis; Diabetes Mellitus, Type 1; Arthritis, Juvenile; Sjogren's Syndrome; Spondylitis, Ankylosing; Pouchitis; Ichthyosis; Dermatomyositis; Inflammatory Bowel Diseases; Type I Leukocyte Adhesion Defect; Polymyositis; Liver Cirrhosis, Biliary | Details |
Ustekinumab biosimilar(Formycon) | FYB-202 | Approved | Formycon AG | OTULFI | EU | Crohn Disease; Colitis, Ulcerative | Fresenius Kabi Deutschland Gmbh, Formycon AG | 2024-09-25 | Arthritis, Psoriatic; Colitis, Ulcerative; Plaque psoriasis; Crohn Disease | Details |
Ustekinumab Biosimilar (qyuns) | QX-001S; QX-001-S; HDM-3001 | Approved | Qyuns Therapeutics Co Ltd | Mainland China | Plaque psoriasis | Qyuns Therapeutics Co Ltd | 2024-10-29 | Psoriasis; Plaque psoriasis | Details | |
Ustekinumab Biosimilar(Celltrion) | CT-P43 | Approved | Celltrion Inc | Steqeyma, Steqeyma IV | Canada | Plaque psoriasis; Arthritis, Psoriatic; Crohn Disease | Celltrion Inc | 2024-08-01 | Psoriasis; Arthritis, Psoriatic; Colitis, Ulcerative; Plaque psoriasis; Crohn Disease | Details |
Ustekinumab biosimilar (Biocon) | Approved | Biocon Biologics Ltd | Bmab 1200, Yesintek | United States | Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease | Biocon Biologics Inc | 2024-11-29 | Psoriasis; Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease; Plaque psoriasis | Details | |
Ustekinumab biosimilar (Alvotech) | AVT04; AVT-04 | Approved | Alvotech hf | Jamteki, Uzpruvo, SELARSDI™, JamtekiTM, Ustekinumab BS (F) | Japan | Arthritis, Psoriatic; Psoriasis | Fuji Pharma Co Ltd | 2023-09-25 | Psoriasis; Arthritis, Psoriatic; Colitis, Ulcerative; Plaque psoriasis; Crohn Disease | Details |
Ustekinumab biosimilar(Amgen) | ABP-654 | Approved | Amgen Inc | Wezlana, WEZLANA, wezenla | United States | Crohn Disease; Colitis, Ulcerative; Arthritis, Psoriatic; Plaque psoriasis | Amgen Inc | 2023-10-31 | Psoriasis; Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease; Plaque psoriasis | Details |
Ustekinumab biosimilar(DM Bio) | DA-3115; DMB-3115 | Approved | Dong-A Pharmaceutical Co Ltd, Meiji Seika Pharma Co Ltd | IMULDOSA, Absimky | United States | Psoriasis | Dong-A ST Co Ltd, Meiji Seika Kaisha Ltd | 2024-10-11 | Psoriasis; Colitis, Ulcerative; Crohn Disease | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Brazikumab | AMG-139; MEDI-2070; Anti-IL-23-MAb (Amgen) | Phase 2 Clinical | Amgen Inc | Inflammatory Bowel Diseases; Psoriasis; Colitis, Ulcerative; Crohn Disease | Details |
mRNA-2752 | mRNA-2752 | Phase 1 Clinical | Moderna Inc, Astrazeneca Plc | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Lymphoma, Non-Hodgkin; Lymphoma; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
SFA-002 | SFA-002; SFA002 | Phase 1 Clinical | Arthritis, Rheumatoid; Plaque psoriasis | Details | |
IL-23/CGRP bispecific antibody (Lilly) | Phase 1 Clinical | Eli Lilly And Company | Autoimmune Diseases | Details | |
Ustekinumab biosimilar (Curateq Biologics) | BP38; BP-38 | Phase 1 Clinical | CuraTeQ Biologics Pvt Ltd | Psoriasis | Details |
Ustekinumab Biosimilar (NeuClone/Serum Institute of India) | Phase 1 Clinical | Neuclone, Serum Institute Of India Ltd | Autoimmune Diseases | Details | |
Ustekinumab biosimilar(Rani Therapeutics) | RT-111 | Phase 1 Clinical | Rani Therapeutics Llc | Psoriasis | Details |
SOR-102 | SOR-102 | Phase 1 Clinical | Sorriso Pharmaceuticals Inc | Inflammatory Bowel Diseases; Colitis, Ulcerative | Details |
Kagocel | Clinical | Nearmedic Plus Llc | Respiratory Tract Infections; Respirovirus Infections; Influenza, Human | Details | |
Ustekinumab biosimilar (BioFactura) | BFI-751 | BioFactura Australia Pty Ltd | Details | ||
Brazikumab | AMG-139; MEDI-2070; Anti-IL-23-MAb (Amgen) | Phase 2 Clinical | Amgen Inc | Inflammatory Bowel Diseases; Psoriasis; Colitis, Ulcerative; Crohn Disease | Details |
mRNA-2752 | mRNA-2752 | Phase 1 Clinical | Moderna Inc, Astrazeneca Plc | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Lymphoma, Non-Hodgkin; Lymphoma; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
SFA-002 | SFA-002; SFA002 | Phase 1 Clinical | Arthritis, Rheumatoid; Plaque psoriasis | Details | |
IL-23/CGRP bispecific antibody (Lilly) | Phase 1 Clinical | Eli Lilly And Company | Autoimmune Diseases | Details | |
Ustekinumab biosimilar (Curateq Biologics) | BP38; BP-38 | Phase 1 Clinical | CuraTeQ Biologics Pvt Ltd | Psoriasis | Details |
Ustekinumab Biosimilar (NeuClone/Serum Institute of India) | Phase 1 Clinical | Neuclone, Serum Institute Of India Ltd | Autoimmune Diseases | Details | |
Ustekinumab biosimilar(Rani Therapeutics) | RT-111 | Phase 1 Clinical | Rani Therapeutics Llc | Psoriasis | Details |
SOR-102 | SOR-102 | Phase 1 Clinical | Sorriso Pharmaceuticals Inc | Inflammatory Bowel Diseases; Colitis, Ulcerative | Details |
Kagocel | Clinical | Nearmedic Plus Llc | Respiratory Tract Infections; Respirovirus Infections; Influenza, Human | Details | |
Ustekinumab biosimilar (BioFactura) | BFI-751 | BioFactura Australia Pty Ltd | Details |
This web search service is supported by Google Inc.